These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 26881541)

  • 1. Transformation from atypical chronic myeloid leukemia to chronic myelomonocytic leukemia as progression of myeloid neoplasm with platelet-derived growth factor ß rearrangement.
    Shi X; Su Z; Zhao C; Feng X
    J Cancer Res Ther; 2015; 11(4):914-6. PubMed ID: 26881541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid/Lymphoid Neoplasm with PDGFRB Rearrangement with t (5;10) (q33;q22) Harboring a Novel Breakpoint of the CCDC6-PDGFRB Fusion Gene.
    Yamazaki M; Nakaseko C; Takeuchi M; Ozawa S; Ishizuka Y; Hatanaka Y; Oshima-Hasegawa N; Muto T; Tsukamoto S; Mitsukawa S; Ohwada C; Takeda Y; Mimura N; Iseki T; Fukazawa M; Sakaida E
    Intern Med; 2019 Dec; 58(23):3449-3453. PubMed ID: 31327842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted next generation sequencing of PDGFRB rearranged myeloid neoplasms with monocytosis.
    Patnaik MM; Lasho TL; Finke CM; Pardanani A; Tefferi A
    Am J Hematol; 2016 Mar; 91(3):E12-4. PubMed ID: 26662677
    [No Abstract]   [Full Text] [Related]  

  • 4. Eosinophilia in Hematologic Disorders.
    Falchi L; Verstovsek S
    Immunol Allergy Clin North Am; 2015 Aug; 35(3):439-52. PubMed ID: 26209894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions.
    Muramatsu H; Makishima H; Maciejewski JP
    Semin Oncol; 2012 Feb; 39(1):67-73. PubMed ID: 22289493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia.
    Li B; Gale RP; Xiao Z
    J Hematol Oncol; 2014 Dec; 7():93. PubMed ID: 25498990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The usefulness of the bcr/abl rearrangement in the diagnosis and evolution of chronic myeloid leukemia].
    González FA; Villegas A; Ferro MT; San Román C; Sáez I; López M; del Potro E; Alvarez A; Martínez R; Díaz Madiavilla J
    Med Clin (Barc); 1993 Oct; 101(14):521-4. PubMed ID: 8231395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a rare e6a2 BCR-ABL fusion gene during the disease progression of chronic myelomonocytic leukemia: a case report.
    Hayette S; Tigaud I; Thomas X; French M; Perrin MC; Nicolini F; Michallet M; Magaud JP
    Leukemia; 2004 Oct; 18(10):1735-6. PubMed ID: 15356652
    [No Abstract]   [Full Text] [Related]  

  • 9. [Blast crisis accompanied by severe DIC of Ph negative chronic myeloid leukemia showing t(9;16) and positive M-BCR/ABL rearrangement].
    Fujiwara H; Takahashi N; Tada J; Higuchi T; Harada H; Mori H; Niikura H; Omine M; Fujita K
    Rinsho Ketsueki; 1997 Aug; 38(8):663-68. PubMed ID: 9311272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneous features of Ph-negative CML--possible existence of Ph-negative, bcr-rearrangement-negative CML.
    Kato Y; Sawada H; Tashima M; Yumoto Y; Okuda T; Ueda T; Yamagishi M; Uchino H
    Nihon Ketsueki Gakkai Zasshi; 1989 Sep; 52(6):1004-12. PubMed ID: 2588950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase.
    Jawhar M; Naumann N; Schwaab J; Baurmann H; Casper J; Dang TA; Dietze L; Döhner K; Hänel A; Lathan B; Link H; Lotfi S; Maywald O; Mielke S; Müller L; Platzbecker U; Prümmer O; Thomssen H; Töpelt K; Panse J; Vieler T; Hofmann WK; Haferlach T; Haferlach C; Fabarius A; Hochhaus A; Cross NCP; Reiter A; Metzgeroth G
    Ann Hematol; 2017 Sep; 96(9):1463-1470. PubMed ID: 28725989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breakpoint cluster region, immunoglobulin, and T-cell receptor gene rearrangement analysis in juvenile chronic myelogenous leukemia.
    Farhi DC; Luckey CN; Siddiqui AM
    Mod Pathol; 1995 May; 8(4):389-93. PubMed ID: 7567936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of myelopoiesis-associated microRNA in bone marrow cells of atypical chronic myeloid leukaemia and chronic myelomonocytic leukaemia.
    Hussein K; Büsche G; Muth M; Göhring G; Kreipe H; Bock O
    Ann Hematol; 2011 Mar; 90(3):307-13. PubMed ID: 20842500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Molecular characterization of atypical chronic myeloid leukemia and chronic neutrophilic leukemia].
    Senín A; Arenillas L; Martínez-Avilés L; Fernández-Rodríguez C; Bellosillo B; Florensa L; Besses C; Álvarez-Larrán A
    Med Clin (Barc); 2015 Jun; 144(11):487-90. PubMed ID: 24854193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic use of fluorescence in-situ hybridisation and clinicopathological features in the screening of PDGFRB rearrangements of patients with myeloid/lymphoid neoplasms.
    Fang H; Tang G; Loghavi S; Greipp P; Wang W; Verstovsek S; Medeiros LJ; Reichard KK; Miranda RN; Wang SA
    Histopathology; 2020 Jun; 76(7):1042-1054. PubMed ID: 32083752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
    Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
    N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pediatric myeloid neoplasms associated with eosinophilia and platelet-derived growth factor receptor beta gene rearrangement: a case report and literature review].
    Zhang XY; Liu TF; Li CW; Li QH; Zhu XF
    Zhonghua Er Ke Za Zhi; 2018 Jan; 56(1):34-38. PubMed ID: 29342995
    [No Abstract]   [Full Text] [Related]  

  • 18. Marked response to imatinib mesylate in a patient with platelet-derived growth factor receptor beta-associated acute myeloid leukemia.
    Shimomura Y; Maruoka H; Ishikawa T
    Int J Hematol; 2017 May; 105(5):697-701. PubMed ID: 28000100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T lymphoid/myeloid bilineal crisis in chronic myelogenous leukemia.
    Akashi K; Mizuno S; Harada M; Kimura N; Kinjyo M; Shibuya T; Shimoda K; Takeshita M; Okamura S; Matsumoto I
    Exp Hematol; 1993 Jun; 21(6):743-8. PubMed ID: 7684698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm.
    Fend F; Horn T; Koch I; Vela T; Orazi A
    Leuk Res; 2008 Dec; 32(12):1931-5. PubMed ID: 18555525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.